Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sean E Connolly

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
Rheumatology and Therapy|March 15, 2019
Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona RegistryLeslie R Harrold, Heather J Litman, Sean E Connolly, et al.
The Journal of Rheumatology|November 3, 2017
Effect of Anticitrullinated Protein Antibody Status on Response to Abatacept or Antitumor Necrosis Factor-α Therapy in Patients with Rheumatoid Arthritis: A US National Observational StudyLeslie R Harrold, Heather J Litman, Sean E Connolly, et al.
Clinical Rheumatology|March 3, 2017
A window of opportunity for abatacept in RA: is disease duration an independent predictor of low disease activity/remission in clinical practice?Leslie R Harrold, Heather J Litman, Sean E Connolly, et al.
Rheumatology International|May 26, 2020
Disease activity and patient-reported outcomes in patients with rheumatoid arthritis and Sjögren's syndrome enrolled in a large observational US registryLeslie R Harrold, Ying Shan, Sabrina Rebello, et al.
The Journal of Rheumatology|July 3, 2018
Do Poor Prognostic Factors in Rheumatoid Arthritis Affect Treatment Choices and Outcomes? Analysis of a US Rheumatoid Arthritis RegistryEvo Alemao, Heather J Litman, Sean E Connolly, et al.
Clinical Rheumatology|March 5, 2020
Prevalence of Sjögren's syndrome associated with rheumatoid arthritis in the USA: an observational study from the Corrona registryLeslie R Harrold, Ying Shan, Sabrina Rebello, et al.
Rheumatology and Therapy|December 23, 2021
Baseline Anti-Citrullinated Protein Antibody Status and Response to Abatacept or Non-TNFi Biologic/Targeted-Synthetic DMARDs: US Observational Study of Patients with RALeslie R Harrold, Sean E Connolly, Keith Wittstock, et al.
Rheumatology (Oxford, England)|February 9, 2022
Implementation of the OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Scoring System in a randomized phase IIb study of abatacept in psoriatic arthritisMikkel Østergaard, Paul Bird, Chahin Pachai, et al.
Ochsner Journal|October 14, 2017
Use of Digital Pupillometry to Measure Sedative Response to PropofolJody H Haddock, Donald E Mercante, Rose Paccione, et al.
Annals of the Rheumatic Diseases|September 12, 2015
Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trialJeremy Sokolove, Michael Schiff, Roy Fleischmann, et al.
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
Rheumatology and Therapy|March 15, 2019
Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona RegistryLeslie R Harrold, Heather J Litman, Sean E Connolly, et al.
The Journal of Rheumatology|November 3, 2017
Effect of Anticitrullinated Protein Antibody Status on Response to Abatacept or Antitumor Necrosis Factor-α Therapy in Patients with Rheumatoid Arthritis: A US National Observational StudyLeslie R Harrold, Heather J Litman, Sean E Connolly, et al.
Clinical Rheumatology|March 3, 2017
A window of opportunity for abatacept in RA: is disease duration an independent predictor of low disease activity/remission in clinical practice?Leslie R Harrold, Heather J Litman, Sean E Connolly, et al.
Rheumatology International|May 26, 2020
Disease activity and patient-reported outcomes in patients with rheumatoid arthritis and Sjögren's syndrome enrolled in a large observational US registryLeslie R Harrold, Ying Shan, Sabrina Rebello, et al.
The Journal of Rheumatology|July 3, 2018
Do Poor Prognostic Factors in Rheumatoid Arthritis Affect Treatment Choices and Outcomes? Analysis of a US Rheumatoid Arthritis RegistryEvo Alemao, Heather J Litman, Sean E Connolly, et al.
Clinical Rheumatology|March 5, 2020
Prevalence of Sjögren's syndrome associated with rheumatoid arthritis in the USA: an observational study from the Corrona registryLeslie R Harrold, Ying Shan, Sabrina Rebello, et al.
Rheumatology and Therapy|December 23, 2021
Baseline Anti-Citrullinated Protein Antibody Status and Response to Abatacept or Non-TNFi Biologic/Targeted-Synthetic DMARDs: US Observational Study of Patients with RALeslie R Harrold, Sean E Connolly, Keith Wittstock, et al.
Rheumatology (Oxford, England)|February 9, 2022
Implementation of the OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Scoring System in a randomized phase IIb study of abatacept in psoriatic arthritisMikkel Østergaard, Paul Bird, Chahin Pachai, et al.
Ochsner Journal|October 14, 2017
Use of Digital Pupillometry to Measure Sedative Response to PropofolJody H Haddock, Donald E Mercante, Rose Paccione, et al.
Annals of the Rheumatic Diseases|September 12, 2015
Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trialJeremy Sokolove, Michael Schiff, Roy Fleischmann, et al.
Pageof 4